Celgene Establishing Limited Distribution Network for Otezla

Celgene’s recently approved Otezla is a new medication for the treatment of psoriatic arthritis.

Otezla is an oral small-molecule inhibitor of phosphodiesterase 4 (PDE4) specific for cyclic adenosine monophosphate (cAMP).

Celgene recently selected a limited number of specialty pharmacies to distribute Otezla, including: Diplomat, Avella Specialty Pharmacy, ReCept Pharmacy, and CareMed Pharmaceutical Services.

Celgene’s new psoriatic arthritis drug Otezla will be competing against current offerings from AbbVie , Johnson & Johnson, and Amgen.

Otezla is taken orally, giving Celgene a distinct advantage in the market.